蝇蛆油促进大鼠皮肤机械损伤愈合作用及机制研究

目的:本文拟研究蝇蛆油对皮肤机械损伤的治疗作用及作用机制。方法:SD大鼠随机分为正常组、模型组、蝇蛆油组和重组牛碱性成纤维细胞生长因子(rb-bFGF)凝胶组,制作大鼠皮肤机械性损伤模型,在不同时间点采集样本,检测创面愈合率、创面愈合时间、血管内皮生长因子(VEGF)含量、丙二醛(MDA)和超氧化物歧化酶(SOD)水平,并检测组织中胶原蛋白Ⅰ、胶原蛋白Ⅲ、血小板衍生因子(PDGF)和细胞角蛋白19(CK19)表达情况。结果:模型组大鼠创面愈合时间为29.5±2.6 d,而蝇蛆油创面愈合时间为22.4±2.8 d,存在显著差异(P0.01)。VEDF含量在模型组和给药组均随着创面愈合时间增加,给药组在第1 d即显著高于模型组(P0.01),并在第21 d达到最大值(2051.5±148.2 ng/L)。模型组大鼠创面组织中MDA含量为6.47±0.92 nmo L/mg,SOD含量为7.52±3.21 U/mg,而蝇蛆油给药组大鼠创面组织中MDA含量为3.42±0.83 nmo L/mg,SOD含量为21.32±2.94 U/mg,存在显著差异(P0.01)。进一步研究发现,与模型组比较,蝇蛆油给药组大鼠创面组织中胶原蛋白Ⅰ、胶原蛋白Ⅲ、PDGF和CK19含量均显著升高(P0.01)。结论:蝇蛆油能够促进机械性损伤皮肤创面愈合,其作用机制可能是通过促进血管生成,抗氧化损伤,促进胶原生成,诱导干细胞形成,从而促进创面愈合。     

β-乳香酸对血瘀证大鼠血液流变学和血管内皮功能的影响

目的:研究β-乳香酸(β-BA)对血瘀证大鼠血液流变学和血管内皮功能的影响。方法:24只SD大鼠随机分为4组:空白对照组、模型组、低剂量β-BA(100 mg/kg)组、高剂量β-BA(200 mg/kg)组,每组6只,每12小时给药1次、连续给药7次,第5次给药后,除空白组大鼠外,给予皮下注射盐酸肾上腺素(0.8 mg/kg)2次,间隔4小时,中间给予冰水(0-2℃)刺激5分钟造成大鼠急性血瘀证模型。最后一次给药30分钟内腹主动脉取血检测不同切变率下的全血粘度(WBV)、凝血指标、血浆内皮素-1(ET-1)、一氧化氮(NO)浓度,并取颈动脉观察病理变化。结果:与空白对照组相比,模型组全血粘度明显升高(P0.01),凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)显著缩短(P0.01),纤维蛋白原(FIB)含量增加(P0.01),血浆ET-1水平升高,血浆NO含量降低(P0.01)。与模型组相比,β-BA组全血粘度明显降低,TT、APTT、PT显著延长(P0.01),纤维蛋白原含量减少(P0.01),血浆ET-1水平降低,血浆NO水平升高(P0.01)。结论:β-乳香酸能显著改善血瘀证大鼠血液流变学异常,并保护其血管内皮功能。     

黄芪红花配伍对大鼠脑缺血后血管新生及Cav-1/VEGF信号通路的影响

目的:黄芪红花配伍是否通过调节小凹蛋白1(Caveolin-1,Cav-1)/血管内皮生长因子(vascular endothelial growth factor,VEGF)通路促进血管新生保护大鼠脑缺血损伤。方法:60只雄性SD大鼠随机分为5个组:对照组(Sham组,n=12),模型组(MACO组,n=12),黄芪红花40:1组(n=12),20:1组(n=12),5:1(n=12)。大鼠脑缺血再灌注损伤模型采用尼龙线栓法制作,连续给药21d后,评价神经功能学评分,计算脑梗死体积,采用免疫组化法测定皮质区的微血管密度,采用RT-PCR法检测皮质区VEGF m RNA和Cav-1 m RNA表达,采用Western-blotting法测定皮质区VEGF和Cav-1的蛋白表达。结果:连续给药21d后,各组大鼠的神经功能学评分均有所降低,3个不同比例的黄芪红花组的神经功能学评分降低最为明显(P0.01),脑梗死体积较模型组显著减少(P0.05~P0.01),微血管密度、VEGF和Cav-1 m RNA和蛋白表达水平均较模型组明显升高(P0.05~P0.01)。结论:黄芪红花配伍可能通过调节Cav-1/VEGF信号通路促进脑缺血再灌注损伤大鼠脑内的血管新生,从而减轻脑缺血损伤,且最佳的配伍比例为黄芪红花5:1。     

红景天对心肌梗死大鼠缺血心肌血管新生作用及对VEGF的影响

目的:探讨中药红景天对急性心肌梗死大鼠缺血心肌血管新生作用及其对血管内皮生长因子(EGF)蛋白和mRNA表达的影响.方法:52只SD大鼠随机分成单纯手术组、术后给药组、提前给药组、假手术组和正常对照组.采用开胸结扎冠状动脉左前降支的方法建立心肌梗死模型,4周后处死动物.Ⅷ因子免疫组化染色后对各组大鼠梗死边缘区微血管进行计数;免疫组化技术及Western blot技术检测各组缺血心肌VEGF蛋白质水平表达变化;逆转录多聚酶链反应(RT-PCR)法检测缺血心肌VEGF mR-NA表达变化.结果:术后给药组和提前给药组血管计数均较单纯手术组增多(P＜0.01),且提前给药组明显多于术后给药组(P＜0.01);术后给药组和提前给药组缺血心肌VEGF及其mRNA表达较单纯手术组增加(P＜0.01),提前给药组缺血心肌VEGF及其mRNA表达明显高于术后给药组(P＜0.01).结论:红景天能够促进心梗后大鼠缺血心肌血管新生,其作用机制可能与上调局部心肌VEGF及其mRNA表达有关.预给红景天可能增强对心梗大鼠的上述作用.     

海带多糖对肾上腺素致血管内皮细胞损伤的防护作用

目的：探讨海带多糖L01对肾上腺素（Adr）致血管内皮细胞（VEC）损伤的保护作用。方法：采用注射Adr法建立vEc损伤大鼠模型,主动脉切片免疫组化检测血管内皮受损情况,ELISA法测定大鼠血浆血管性血友病因子（von Willebrand factor,vWF）含量;体外培养人脐静脉内皮细胞（HUVEC）,ELISA法测定HUVEC培养液vWF含量,观察L01对vEC损伤大鼠和Adr刺激HUVEC后vWF生成的影响。结果：造模第4d和第5d主动脉切片免疫组化检测完整内皮层长度（μm）显示,L01高剂量（50mg／kg）、低剂量（10mg／kg）组长度明显高于模型组（P〈0.05）;造模第4d,L01高剂量组大鼠血浆vWF水平低于模型组,两者比较有显著性差异（P〈0.05）,第5dL01高、低剂量组大鼠血浆vwF水平均低于模型组（P〈0.05）。在HUVEC培养实验中,终浓度为0.01mg／ml和0.1mg／ml的L01均能降低24h培养液vwF水平,终浓度为0．1mg／mlL01还能降低48h培养液vwF水平,与Adr组比较有显著性差异（P〈0.05）。结论：L01对vEC具有保护作用。     

阿托伐他汀防鼠颈动脉再狭窄与血清VEGF相关性实验研究

目的:探讨阿托伐他汀防再狭窄效应与促内皮生长作用最强的细胞因子——血管内皮生长因子(VEGF)血清浓度的相关性。方法:24只健康SD大鼠均分为假手术组、模型组与阿托伐他汀组,后两组行颈总动脉球囊损伤造模,损伤前及1周后分别测VEGF血清浓度,4周后观察再狭窄程度。结果:(1)模型组与阿托伐他汀干预组1周后VEGF血清浓度均显著升高,其中阿托伐他汀干预组VEGF增幅高于模型组;(2)阿托伐他汀干预组VEGF增幅与再狭窄程度呈线性负相关。结论:他汀类药物防治再狭窄的机制可能涉及促泌VEGF从而加速内皮修复。     

人参皂甙对气虚型血管损伤中COX-2和iNOS相互作用的影响

探讨气虚型大鼠血管内皮损伤中COX-2和iNOS的蛋白水平及其相互作用,以及人参皂甙的防治作用.用高L-蛋氨酸复制SD大鼠血管内皮损伤,并附以负重游泳法制造气虚实验模型.应用Western blotting分析内皮损伤相关的COX-2和iNOS蛋白水平的变化,免疫共沉淀和激光共聚焦显微镜技术,探讨两者的相互作用,光镜和电镜分析血管内皮的病理变化.结果显示:模型组、COX-2和iNOS蛋白含量显著增高,并存在明显的相互作用,与血管内皮的病理损伤相一致;与模型组相比,人参皂甙组COX-2和iNOS的蛋白含量降低,且两者的相互作用减弱.气虚型大鼠血管内皮损伤中,COX-2和iNOS蛋白含量增高,且两者之间的相互作用增强,加重血管内皮损伤,人参皂甙能够纠正这些异常,起到保护血管内皮免受损伤的作用.     

盐酸氨溴索对烟所致慢性阻塞性肺疾病大鼠肺组织细胞凋亡和血管重塑的作用机制研究

目的:盐酸氨溴索对烟所致慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)大鼠肺组织细胞凋亡和血管重塑的作用机制研究。方法:将SD大鼠随机分为4组,每组20只,依次为正常组、模型组、实验组、对照组。模型组、实验组、对照组大鼠采延安香烟烟熏64天构建慢性阻塞性肺大鼠模型,正常组大鼠室温下正常饲养。烟熏结束后,实验组、对照组大鼠每日分别皮下注射5ml盐酸氨溴索(20 mg/kg)和5 m L的盐酸班布特罗(20 mg/kg),正常组、模型组分别腹腔注射等剂量的生理盐水。在药物干预28天后,苏木精-伊红染色(hematoxylin-eosinstaining,HE)、弹力纤维(elastic van gieson,EVG)染色、TUNNEL染色、免疫组化染色、Western blot检测各组大鼠肺组织病理、血管重塑、肺组织的细胞凋亡、α-平滑肌肌动蛋白(α-smoothmus-cleactin,α-SMA)和血管内皮生长因子(Vascular endothelial growth factor,VEGF)的表达、以及Caspase-3、Bax和Bcl-2的表达水平。结果:与正常组相比,模型组肺组织损伤明显,肺小动脉中膜厚度明显增加,血管肌化程度、细胞的凋亡率、α-SMA和VEGF、Caspase-3、Bax的表达明显升高,Bcl-2的表达明显降低,差异均具有统计学意义(P0.05);与模型组相比,实验组和对照组大鼠肺组织损伤明显改善,肺小动脉中膜厚度明显减小,血管肌化程度、细胞的凋亡率、α-SMA和VEGF、Caspase-3、Bax的表达明显降低,Bcl-2的表达明显升高,差异均具有统计学意义(P0.05)。结论:盐酸氨溴索能抑制肺组织的细胞凋亡以及改善其血管重塑,保护COPD大鼠的肺组织。     

小檗碱对缺血性脑梗死大鼠氧化应激/炎症反应、血管生成的作用研究

摘要 目的：探讨小檗碱对缺血性脑梗死大鼠氧化应激/炎症反应、血管生成的作用。方法：选取60只SPF级SD大鼠,随机分为对照组、模型组和小檗碱组各20只。建立大鼠脑缺血再灌注损伤模型。术后及给药后7d采用Longa标准评分评估大鼠神经功能。检测各组大鼠脑组织的抗氧化活性和炎症因子水平。采用免疫组化检测脑缺血再灌注皮质微血管密度（MVD）。采用实时定量聚合酶链反应（qRT-PCR）检测低氧诱导生长因子- 1 （HIF-1 ）和血管内皮生长因子（VEGF） mRNA表达水平。采用蛋白免疫印迹试验检测VEGF和HIF-1 蛋白表达水平。结果：模型组和小檗碱组大鼠术后具有神经功能缺损症状表现,Longa评分均高于对照组。给药7 d后,模型组和小檗碱组大鼠Longa评分均高于对照组（P＜0.05）,且小檗碱组大鼠Longa评分低于模型组（P＜0.05）。与对照组比较,模型组丙二醛（MDA）水平显著升高,而谷胱甘肽过氧化物酶（GSH-Px）和超氧化物岐化酶（SOD）活性显著降低（P＜0.05）。与模型组比较,小檗碱组MDA水平显著降低,而GSH-Px和SOD活性显著升高（P＜0.05）。与对照组比较,模型组白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）水平显著升高（P＜0.05）。与模型组比较,小檗碱组IL-1β、TNF-α水平显著降低,差异有统计学意义（P＜0.05）。给药7 d后,模型组和小檗碱组MVD、VEGF mRNA和HIF-1 mRNA表达水平均高于对照组（P＜0.05）,而小檗碱组MVD、VEGF mRNA和HIF-1 mRNA表达水平高于模型组（P＜0.05）。给药7 d后,小檗碱组和模型组VEGF和HIF-1 蛋白表达水平均高于对照组（P＜0.05）,而小檗碱组VEGF和HIF-1 蛋白表达水平高于模型组（P＜0.05）。结论：小檗碱通过抑制氧化应激/炎症反应、促进血管生成从而达到脑保护作用,其机制可能与激活HIF-1 /VEGF信号通路有关。     

SURZB/Kir6.1通道开放剂纳他卡林对低氧致大鼠主动脉内皮细胞损伤的保护作用

目的:探讨纳他卡林对低氧引起大鼠主动脉内皮细胞损伤的保护作用及其机制。方法:选取大鼠主动脉内皮细胞作为体外低氧损伤的细胞模型,分为正常对照组、低氧模型组、纳他卡林低、中、高剂量组,利用MTT法测定细胞生存率,硝酸还原酶法检测一氧化氮(NO)释放,RT-PCR法检测细胞间粘附因子-1(ICAM-1)、内皮素-1(ET-1)、血管内皮生长因子(VEGF)mRNA水平。结果:纳他卡林三个剂量组均可逆转低氧所致的血管内皮细胞功能改变,包括提高内皮细胞生存活力和NO的释放水平,显著抑制低氧引发的内皮细胞ICAM-1,ET-1,VEGF mRNA表达量的上调。结论:纳他卡林对低氧诱发的血管内皮细胞分泌功能改变、细胞通透性增加及炎性因子的分泌均具有保护作用。     

Characterization of vascular endothelial growth factor (VEGF) in the uterine cervix over pregnancy: effects of denervation and implications for cervical ripening.

Bilateral neurectomy of the pelvic nerve (BLPN) that carries uterine cervix-related sensory nerves induces dystocia, and administration of its vasoactive neuropeptides induces changes in the cervical microvasculature, resembling those that occur in the ripening cervix. This study was designed to test the hypothesis that (a) the cervix of pregnant rats expresses vascular endothelial growth factor (VEGF) and components of the angiogenic signaling pathway [VEGF receptors (Flt-1, KDR), activity of protein kinase B, Akt (phosphorylated Akt), and endothelial nitric oxide synthase (eNOS)] and von Willebrand Factor (vWF) and that these molecules undergo changes with pregnancy, and (b) bilateral pelvic neurectomy (BLPN) alters levels of VEGF concentration in the cervix. Using RT-PCR and sequencing, two VEGF isoforms, 120 and 164, were identified in the rat cervix. VEGF, VEGF receptor-1 (Flt-1), eNOS, and vWF immunoreactivities (ir) were localized in the microvasculature of cervical stroma. Their protein levels increased during pregnancy but decreased to control levels by 2 days postpartum. VEGF receptor-2 (KDR)-ir was confined to the epithelium of the endocervix. BLPN downregulated levels of VEGF by a third. Therefore, the components of the angiogenic signaling pathway are expressed in the cervix and change over pregnancy. Furthermore, angiogenic and sensory neuronal factors may be important in regulating the dynamic microvasculature in the ripening cervix and may subsequently play a role in cervical ripening and the birth process.     

Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis

We have examined the expression and function of the angiogenic factor, vascular endothelial growth factor (VEGF) during the evolution of type II collagen-induced arthritis (CIA). Biologically active VEGF was expressed along a time course that paralleled the expression of two specific VEGF receptors, Flk-1 and Flt-1, and the progression of joint disease. Moreover, levels of VEGF expression correlated with the degree of neovascularization, as defined by vWF levels, and arthritis severity. Macrophage- and fibroblast-like cells, which infiltrated inflamed sites and were then activated by other inflammatory mediators, are probably important sources of VEGF and may thus regulate angiogenesis during the development of CIA. Administration of anti-VEGF antiserum to CIA mice before the onset of arthritis delayed the onset, reduced the severity, and diminished the vWF content of arthritic joints. By contrast, administration of anti-VEGF antiserum after the onset of the disease had no effect on the progression or ultimate severity of the arthritis. These data suggest that VEGF plays a crucial role during an early stage of arthritis development, affecting both neovascularization and the progression of experimentally induced synovitis.     

Inhibitory role of adiponectin peptide I on rat choroidal neovascularization

Age-related macular degeneration (AMD) is a leading cause of central blindness in the elderly population. The wet type of AMD is characterized by extensive growth of new vessels. One of the effective strategies to treat wet AMD is to limit the choroidal neovascularization (CNV). We studied the effects of adiponectin peptide I (APNpI) on new vessel growth in laser-induced rat model of wet AMD and on rat choroidal endothelial cell (CEC) culture. CNV size and vessel density were investigated by microscopy. Immunohistochemical staining (IHC) for von Willebrand Factor (vWF), APN, APN receptors 1 (AdipoR1), 2 (AdipoR2), VEGF, VEGF receptor 2 (VEGF-R2), proliferating cell nuclear antigen (PCNA) was performed in CNV area. The mRNA expression of VEGF and VEGF-R2 in RPE-choroid was investigated by RT-PCR and real-time PCR. APNpI inhibited area of CNV by 4 fold, number of vWF positive vessels by 99% and area of subretinal tissue by 40%. The expression of VEGF and VEGF-R2 at mRNA and protein levels decreased after APNpI treatment in vivo. Proliferative index (PCNA) was 5 folds less in laser spots of APNpI treated rats compared to controls. In conclusion, APNpI inhibited formation of new vessels in rat model of CNV by decreasing VEGF, VEGF-R2 expression and cell proliferation. Thus, APNpI may have potential therapeutic use for AMD treatment since it significantly inhibited CNV.     

Endothelial activation and injury by cigarette smoke exposure

Endothelial activation/injury following exposure to cigarette smoke may explain incidence of atherosclerosis and cardiovascular disease in smokers. We investigated cigarette smoke extract (CSE) effects relative to activation, injury, and survival of human umbilical vein endothelial cells (HUVEC) and compared circulating levels of specific endothelial activation markers between smokers and healthy non-smokers before and after smoking cessation. Viability and toxicity of HUVEC were tested by MTT and LDH assay. Release (by endothelial cells) and circulating levels (in smokers) of von Willebrand Factor (vWF), thrombomodulin (TM), was evaluated by ELISA. Incubation with increasing concentrations of CSE reduced the percentage of viable cells, being 33.9%, 23.9% after CSE 4%, 6% respectively. Dose- and time-dependent release of LDH was observed after incubation with CSE. vWF, TM release were assayed after CSE 2% HUVEC stimulation. Significant 42%, 61%, 76% increase in vWF concentration was detected respectively at 30', 60', 120'. Reduction in circulating levels of vWF, from a median value of 144.0% to 123.7%, was observed in the quitters group after smoking cessation. Exposure to cigarette smoke is cytotoxic and induces activation/injury of endothelium in vitro and in vivo. These findings may provide pathogenetic basis by which smoking can predispose to development of atherothrombosis and cardiovascular disease.     

Elevated Soluble VEGF Receptor sFlt-1 Correlates with Endothelial Injury in IgA Nephropathy

Background

Endothelial injury, which may present clinically as hypertension, proteinuria and increased von Willebrand Factor (vWF) level, is a common manifestation in IgA nephropathy (IgAN). However, causal factors for endothelial injury in IgAN are not completely understood. An imbalance of vascular endothelial growth factor/Soluble fms-like tyrosine kinase-1 (VEGF/sFlt-1) has been observed in many diseases with endothelial dysfunction, including pre-eclampsia and diabetic retinopathy, but whether it contributes to endothelial injury in IgAN requires further exploration.

Methods

Initially, 96 IgAN patients and 22 healthy volunteers were enrolled as a discovery cohort. VEGF/sFlt-1, sFlt-1 and VEGF levels were compared between patients with IgAN and healthy volunteers to explore the underlying factors that contribute to endothelial injury in IgAN. The identified contributor (sFlt-1) was further confirmed in a replication cohort, which included 109 IgAN patients and 30 healthy volunteers. Correlations of sFlt-1 with hypertension, proteinuria, Oxford-E score and plasma vWF were further evaluated in the combined 205 patients with IgAN.

Results

VEGF/sFlt-1 levels were significantly lower in IgAN patients than healthy volunteers (0.33±0.27 vs. 0.43±0.22, p = 0.02) in the discovery cohort. Within the ratio, plasma sFlt-1 levels were significantly elevated (101.18±25.19 vs. 79.73±18.85 pg/ml, p<0.001), but plasma VEGF levels showed no significant differences. Elevated sFlt-1 levels in the replication cohort were confirmed in IgAN patients (93.40±39.78 vs. 71.92±15.78 pg/ml, p<0.001). Plasma sFlt-1 levels in IgAN patients correlated with proteinuria (severe (>3.5 g/d) vs. moderate (1–3.5 g/d) vs. mild (<1 g/d) proteinuria: 115.95±39.09 vs. 99.89±28.55 vs. 83.24±33.92 pg/ml; severe vs. mild: p<0.001, moderate vs. mild p = 0.001, severe vs. moderate: p = 0.014), hypertension (with vs. without hypertension: 107.87±31.94 vs. 87.32±32.76 pg/ml, p = 0.015) and vWF levels (r = 0.161, p = 0.021).

Conclusions

The present study found elevated sFlt-1 in IgAN patients and further identified its correlation with proteinuria, hypertension and vWF levels. These results suggested that elevated sFlt-1 contributes to endothelial injury in IgAN.     

VEGF和IGF-I在子宫内膜异位症患者血清中的表达及临床意义

目的：探究血管内皮生长因子（VEGF）和胰岛素样生长因子-I（IGF-I）在子宫内膜异位症患者血清中的表达及临床意义,为 子宫内膜异位症的治疗提供参考。方法：选取我院2015 年1 月至2016 年1 月收治的子宫内膜异位症患者50 例为实验组,另选 体检中心健康妇女50 例为对照组。实验组患者根据疾病不同分期分为I、II期（n=24）和III、IV 期（n=26）。通过酶联免疫吸附法 （ELISA）检测两组对象血清中VEGF和IGF-I的水平,采用Pearson相关分析法分析实验组患者血清中VEGF 和IGF-I 表达的相 关性。结果：实验组患者血清中VEGF和IGF-I的水平均明显高于对照组,差异有统计学意义（P<0.05）;实验组III、IV期患者血清 中VEGF和IGF-I的水平明显高于I、II期患者,差异有统计学意义（P<0.05）;Pearson 相关性分析显示实验组患者血清中VEGF 和IGF-I的水平变化呈正相关关系（r=0.507,P<0.05）。结论：子宫内膜异位症患者血清中VEGF和IGF-I的水平高于正常水平,并 随着病情的加重而不断升高,且二者呈正相关关系,可协同作用加快病情发展。     

Efficacy of combined medication of nifedipine and magnesium sulfate on gestational hypertension and the effect on PAPP-A,VEGF, NO,Hcy and vWF

ObjectiveTo investigate the effects of combined medication of nifedipine and magnesium sulfate on the blood pressure, pregnancy-associated plasma protein A (PAPP-A), vascular endothelial growth factor (VEGF), nitric oxide (NO), homocysteine (Hcy) and von Willebrand factor (vWF) in gestational hypertension patients.MethodsA total of 220 gestational hypertension patients were enrolled as the subjects, and divided into two groups randomly, i.e. the observation group and the control group. In observation group, patients took combined medication of nifedipine and magnesium sulfate, while those in the control group only took magnesium sulfate for treatment. Clinical efficacy, and the changes in blood pressure, PAPP-A, VEGF, NO, Hcy and vWF before and after treatment were compared between two groups.ResultsIn the observation group and the control group, total effectiveness rates were 92.7% and 70.9%, respectively (p < 0.05). After treatment, we found significant decreases in PAPP-A, VEGF, NO, Hcy and vWF in patients of two groups, with more significant decreases in the observation group (p < 0.05). Incidence rates of the adverse reactions in two groups were 5.5% and 6.4%, respectively, without any statistically significant differences (p > 0.05). In the observation group, patients had fewer complications (p < 0.05).ConclusionCombined medication of magnesium sulfate and nifedipine can decrease the levels of PAPP-A, VEGF, NO, Hcy and vWF in serum as well as the blood pressure of patients with gestational hypertension, with a reduction in incidence rate of complications and improvement in efficacy.     

模拟室内高浓度PM2.5对大鼠血清和组织VEGF蛋白表达的影响

目的:采用"密闭环境熏烟法"模拟PM2.5高浓度环境,建立大鼠被动吸烟模型,观察模拟公共场所室内高浓度PM2.5对正常大鼠血清血管内皮生长因子(VEGF)以及心、脾、肺三种组织VEGF蛋白表达的影响。方法:将20只6月龄雄性健康Wistar大鼠按体重分层随机分为实验组和对照组。并且两组大鼠均于相同的环境下(温度,湿度,光照)进行饲养。对照组不做任何处理,实验组进行为期6周的密闭环境烟熏。末次烟熏结束24-36小时内,用ELISA检测两组大鼠血清VEGF水平的变化,用Western blot检测心、脾、肺三种组织VEGF蛋白表达的变化。结果:与对照组比较,实验组心、脾VEGF1、2以及肺VEGF1蛋白表达水平均显著下降,而肺VEGF2和血清VEGF水平无显著变化。结论:6周模拟公共场所室内高浓度PM2.5能显著降低大鼠心、脾、肺VEGF蛋白表达水平。     

VEGF165 Therapy Exacerbates Secondary Damage Following Spinal Cord Injury

Vascular endothelial growth factor (VEGF) demonstrates potent and well-characterized effects on endothelial cytoprotection and angiogenesis. In an attempt to preserve spinal microvasculature and prolong the endogenous neovascular response observed transiently following experimental spinal cord injury (SCI), exogenous recombinant human VEGF (rhVEGF₁₆₅) was injected into the injured rat spinal cord. Adult female Fischer 344 rats were subjected to moderate SCI (12.5 g-cm) using the NYU impactor. At 72 h after injury, animals were randomly assigned to three experimental groups receiving no microinjection or injection of saline or saline containing 2 g of rhVEGF₁₆₅. Acutely, VEGF injection resulted in significant microvascular permeability and infiltration of leukocytes into spinal cord parenchyma. 6 weeks postinjection, no significant differences were observed in most measures of microvascular architecture following VEGF treatment, but analysis of histopathology in spinal cord tissue revealed profound exacerbation of lesion volume. These results support the idea that intraparenchymal application of the proangiogenic factor VEGF may exacerbate SCI, likely through its effect on vessel permeability.